Bio-Rad Reports First-Quarter 2024 Financial Results
Bio-Rad Laboratories, Inc. Class A (BIO)
Last bio-rad laboratories, inc. class a earnings: 2/13 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
bio-rad.com/en-us/corporate/investor-relations
Company Research
Source: Business Wire
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023.Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter in 2023. The currency-neutral year-over-year sales decrease was broad-based and was primarily driven by ongoing weakness in the biotech and biopharma end-markets and the economic environment in China.Clinical Diagnostics segment net sales for the first qua
Show less
Read more
Impact Snapshot
Event Time:
BIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIO alerts
High impacting Bio-Rad Laboratories, Inc. Class A news events
Weekly update
A roundup of the hottest topics
BIO
News
- Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down [Yahoo! Finance]Yahoo! Finance
- Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.MarketBeat
- Molecular Weight Marker Market Forecast Report 2019-2029, Featuring Bio-Rad Laboratories, Merck, New England Biolabs, Promega, QIAGEN, VWR, Takara Bio, HiMedia Laboratories and GeneDireX [Yahoo! Finance]Yahoo! Finance
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceBusiness Wire
- Liquid Handling Systems Market Size Worth $8.07 billion by 2031 at a CAGR of 7.8%: Straits Research [Yahoo! Finance]Yahoo! Finance
BIO
Earnings
- 5/7/24 - Beat
BIO
Sec Filings
- 5/9/24 - Form SD
- 5/8/24 - Form S-8
- 5/8/24 - Form 10-Q
- BIO's page on the SEC website